Table 1 Characteristics of patients with... | American Society of Hematology

Table 1

Characteristics of patients with MCL

Patient no.	Disease status	Cell source*	Morphologic variant	Tumor cells, %†	p53 status‡	ATM status§	p16 status∥
1	Diagnosis	PB	C	95	WT	del	WT
2	Relapse	PB	C	95	Mut¶	WT	del
3	Diagnosis	PB	C	84	WT	del	WT
4	Diagnosis	PB	C	85	WT	WT	WT
5	Diagnosis	Spleen	C	95	WT	del	WT
6	Diagnosis	Spleen	C	80	WT	WT	WT
7	Diagnosis	PB	C	86	WT	WT	ND
8	Relapse	PB	B	70	WT	WT	WT
9	Diagnosis	Spleen	C	95	WT	ND	WT
10	Diagnosis	PB	C	75	WT	ND	ND
11	Diagnosis	PB	C	72	WT	ND	ND

Patient no.	Disease status	Cell source*	Morphologic variant	Tumor cells, %†	p53 status‡	ATM status§	p16 status∥
1	Diagnosis	PB	C	95	WT	del	WT
2	Relapse	PB	C	95	Mut¶	WT	del
3	Diagnosis	PB	C	84	WT	del	WT
4	Diagnosis	PB	C	85	WT	WT	WT
5	Diagnosis	Spleen	C	95	WT	del	WT
6	Diagnosis	Spleen	C	80	WT	WT	WT
7	Diagnosis	PB	C	86	WT	WT	ND
8	Relapse	PB	B	70	WT	WT	WT
9	Diagnosis	Spleen	C	95	WT	ND	WT
10	Diagnosis	PB	C	75	WT	ND	ND
11	Diagnosis	PB	C	72	WT	ND	ND

PB indicates peripheral blood; C, classical; B, blastoid; WT, normal; del, deleted; and ND, not determined.

Source of the cells used for the in vitro analysis.

Percentages of tumor cells after isolation of mononuclear cells by Ficoll sedimentation.

p53 status assessed by FISH and mutational status analyzed by SSCP and sequencing.

ATM status assessed by FISH.

p16 deletion assessed by real-time PCR.

CGT→CAT (codon 273).